pHR_PGK_antiCD19_synNotch_Gal4VP64 Citations (23)
Originally described in: Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, Lim WA Cell. 2016 Feb 11;164(4):780-91. doi: 10.1016/j.cell.2016.01.012. Epub 2016 Jan 28. PubMed Journal
Articles Citing pHR_PGK_antiCD19_synNotch_Gal4VP64
| Articles |
|---|
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.
Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA, Lim WA.
Cell. 2016 Oct 6;167(2):419-432.e16. doi: 10.1016/j.cell.2016.09.011. Epub 2016 Sep 29.
PubMed
Associated Plasmids |
| Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, Smythe KS, Dudakov JA, Pierce RH, Rader C, Riddell SR. Cancer Cell. 2019 Mar 18;35(3):489-503.e8. doi: 10.1016/j.ccell.2019.02.003. PubMed |
An AND-Gated Drug and Photoactivatable Cre-loxP System for Spatiotemporal Control in Cell-Based Therapeutics.
Allen ME, Zhou W, Thangaraj J, Kyriakakis P, Wu Y, Huang Z, Ho P, Pan Y, Limsakul P, Xu X, Wang Y.
ACS Synth Biol. 2019 Oct 18;8(10):2359-2371. doi: 10.1021/acssynbio.9b00175. Epub 2019 Oct 8.
PubMed
Associated Plasmids |
| Synthetic Notch-Receptor-Mediated Transmission of a Transient Signal into Permanent Information via CRISPR/Cas9-Based Genome Editing. Sgodda M, Alfken S, Schambach A, Eggenschwiler R, Fidzinski P, Hummel M, Cantz T. Cells. 2020 Aug 20;9(9). pii: cells9091929. doi: 10.3390/cells9091929. PubMed |
| Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D. Nat Commun. 2020 Sep 23;11(1):4810. doi: 10.1038/s41467-020-18444-2. PubMed |
| Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, Hogarty MD, Barrett DM, Shimada H, Asgharzadeh S. Nat Commun. 2021 Jan 21;12(1):511. doi: 10.1038/s41467-020-20785-x. PubMed |
| Avidity-Based Selection of Tissue-Specific CAR-T Cells from a Combinatorial Cellular Library of CARs. Ma P, Ren P, Zhang C, Tang J, Yu Z, Zhu X, Fan K, Li G, Zhu W, Sang W, Min C, Chen W, Huang X, Yang G, Lerner RA. Adv Sci (Weinh). 2021 Jan 29;8(6):2003091. doi: 10.1002/advs.202003091. eCollection 2021 Mar. PubMed |
| Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. He H, Liao Q, Zhao C, Zhu C, Feng M, Liu Z, Jiang L, Zhang L, Ding X, Yuan M, Zhang X, Xu J. J Immunother Cancer. 2021 Oct;9(10). pii: jitc-2021-002755. doi: 10.1136/jitc-2021-002755. PubMed |
| CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism. Medler J, Kucka K, Melo V, Zhang T, von Rotenhan S, Ulrich J, Bremer E, Hudecek M, Beilhack A, Wajant H. Theranostics. 2022 Jan 1;12(4):1486-1499. doi: 10.7150/thno.66119. eCollection 2022. PubMed |
| Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. Lubbers JM, Wazynska MA, van Rooij N, Kol A, Workel HH, Plat A, Paijens ST, Vlaming MR, Spierings DCJ, Elsinga PH, Bremer E, Nijman HW, de Bruyn M. Cancers (Basel). 2022 Apr 11;14(8). pii: cancers14081924. doi: 10.3390/cancers14081924. PubMed |
| LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation. Sung E, Ko M, Won JY, Jo Y, Park E, Kim H, Choi E, Jung UJ, Jeon J, Kim Y, Ahn H, Choi DS, Choi S, Hong Y, Park H, Lee H, Son YG, Park K, Won J, Oh SJ, Lee S, Kim KP, Yoo C, Song HK, Jin HS, Jung J, Park Y. Mol Ther. 2022 Aug 3;30(8):2800-2816. doi: 10.1016/j.ymthe.2022.05.003. Epub 2022 May 6. PubMed |
| The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling. Bilemjian V, Vlaming MR, Alvarez Freile J, Huls G, De Bruyn M, Bremer E. Cancers (Basel). 2022 Jun 28;14(13):3164. doi: 10.3390/cancers14133164. PubMed |
| Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy. Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, Unutmaz D. J Immunol. 2022 Oct 15;209(8):1523-1531. doi: 10.4049/jimmunol.2100856. Epub 2022 Sep 7. PubMed |
| Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2. Dogan M, Kozhaya L, Placek L, Karabacak F, Yigit M, Unutmaz D. Clin Transl Immunology. 2022 Oct 21;11(10):e1421. doi: 10.1002/cti2.1421. eCollection 2022. PubMed |
| Engineering inducible biomolecular assemblies for genome imaging and manipulation in living cells. Peng Q, Huang Z, Sun K, Liu Y, Yoon CW, Harrison RES, Schmitt DL, Zhu L, Wu Y, Tasan I, Zhao H, Zhang J, Zhong S, Chien S, Wang Y. Nat Commun. 2022 Dec 24;13(1):7933. doi: 10.1038/s41467-022-35504-x. PubMed |
| Enhancing adoptive T-cell therapy with fucoidan-based IL-2 delivery microcapsules. Jeon EY, Choi DS, Choi S, Won JY, Jo Y, Kim HB, Jung Y, Shin SC, Min H, Choi HW, Lee MS, Park Y, Chung JJ, Jin HS. Bioeng Transl Med. 2022 Jul 5;8(1):e10362. doi: 10.1002/btm2.10362. eCollection 2023 Jan. PubMed |
| Co-opting signalling molecules enables logic-gated control of CAR T cells. Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C, Sotillo E, Weber EW, Rietberg SP, Dalton GN, Yin Y, Klysz D, Xu P, de la Serna EL, Dunn AR, Satpathy AT, Mackall CL, Majzner RG. Nature. 2023 Mar;615(7952):507-516. doi: 10.1038/s41586-023-05778-2. Epub 2023 Mar 8. PubMed |
| Visualizing cell-cell communication using synthetic notch activated MRI. Wang T, Chen Y, Nystrom NN, Liu S, Fu Y, Martinez FM, Scholl TJ, Ronald JA. Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2216901120. doi: 10.1073/pnas.2216901120. Epub 2023 Mar 9. PubMed |
| Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Ruffo E, Butchy AA, Tivon Y, So V, Kvorjak M, Parikh A, Adams EL, Miskov-Zivanov N, Finn OJ, Deiters A, Lohmueller J. Nat Commun. 2023 May 9;14(1):2463. doi: 10.1038/s41467-023-37863-5. PubMed |
| EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells. Melo V, Nelemans LC, Vlaming M, Lourens HJ, Wiersma VR, Bilemjian V, Huls G, de Bruyn M, Bremer E. Front Immunol. 2023 Jul 20;14:1191866. doi: 10.3389/fimmu.2023.1191866. eCollection 2023. PubMed |
| A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity. Lee DH, Ahn H, Sim HI, Choi E, Choi S, Jo Y, Yun B, Song HK, Oh SJ, Denda-Nagai K, Park CS, Irimura T, Park Y, Jin HS. J Exp Clin Cancer Res. 2023 Oct 20;42(1):272. doi: 10.1186/s13046-023-02840-9. PubMed |
| A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay. Fu Y, Wang T, Ronald JA. Front Pharmacol. 2023 Dec 7;14:1304194. doi: 10.3389/fphar.2023.1304194. eCollection 2023. PubMed |
| Expression of modified FcgammaRI enables myeloid cells to elicit robust tumor-specific cytotoxicity. Farhat-Younis L, Na M, Zarfin A, Khateeb A, Santana-Magal N, Richter A, Gutwillig A, Rasoulouniriana D, Gleiberman A, Beck L, Giger T, Ashkenazi A, Barzel A, Rider P, Carmi Y. Elife. 2024 Jun 17;12:RP91999. doi: 10.7554/eLife.91999. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.